Mechanisms of CHD5 inactivation in neuroblastomas

Clinical Cancer Research

Volumn 18, Issue 6, 2012, Pages 1588-1597

  Koyama, Hiroshi ^a   Zhuang, Tiangang ^a   Light, Jennifer E ^a   Kolla, Venkatadri ^a   Higashi, Mayumi ^a   McGrady, Patrick W ^c   London, Wendy B ^c,d   Brodeur, Garrett M ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; CHD5 GENE; CHILD; CHROMOSOME 11Q; CHROMOSOME 1P; CHROMOSOME DELETION; CONTROLLED STUDY; DNA METHYLATION; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE SEQUENCE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MYCN GENE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION;

CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 1; DNA HELICASES; DNA METHYLATION; HUMANS; INFANT; NERVE TISSUE PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RNA, MESSENGER; SEQUENCE DELETION; TRANSFECTION;

EID: 84858238452     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2644     Document Type: Article

References (53)

1. Brodeur GM, Hogarty MD, Mosse YP, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology, 6th ed. Philadelphia: Lippincott; 2010. p. 886-922.
2. Bilke S, Chen QR, Westerman F, Schwab M, Catchpoole D, Khan J. Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol 2005;23:7322-31. (Pubitemid 46202345)
3. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. (Pubitemid 37328872)
4. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, et al. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. PLoS One 2007;2:e255.
5. Janoueix-Lerosey I, Schleiermacher G, Michels E, Mosseri V, Ribeiro A, Lequin D, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026-33.
6. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008;27:441-9.
7. Vandesompele J, Baudis M, De Preter K, Van Roy N, Ambros P, Bown N, et al. Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma. J Clin Oncol 2005;23:2280-99. (Pubitemid 46218721)
8. Attiyeh EF, London WB, Mosse YP, Wang Q, Winter C, Khazi D, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med 2005;353:2243-53. (Pubitemid 41697287)
9. Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci U S A 1989;86:3753-7.
10. Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, et al. Significance of chromosome 1p loss of heterozygosity in neuroblastoma. Cancer Res 1995;55:4664-9.
11. White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci U S A 1995;92:5520-4.
12. Okawa ER, Gotoh T, Manne J, Igarashi J, Fujita T, Silverman KA, et al. Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 2008;27:803-10. (Pubitemid 351186313)
13. White PS, Thompson PM, Gotoh T, Okawa ER, Igarashi J, Kok M, et al. Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 2005;24:2684-94. (Pubitemid 40593096)
14. Bauer A, Savelyeva L, Claas A, Praml C, Berthold F, Schwab M. Smallest region of overlapping deletion in 1p36 in human neuroblastoma: a 1 Mbp cosmid and PAC contig. Genes Chromosomes Cancer 2001;31:228-39. (Pubitemid 32521753)
15. Caron H, Spieker N, Godfried M, Veenstra M, van Sluis P, de Kraker J, et al. Chromosome bands 1p35-36 contain two distinct neuroblastoma tumor suppressor loci, one of which is imprinted. Genes Chrom Cancer 2001;30:168-74. (Pubitemid 32044597)
16. Cheng NC, Van Roy N, Chan A, Beitsma M, Westerveld A, Speleman F, et al. Deletion mapping in neuroblastoma cell lines suggests two distinct tumor suppressor genes in the 1p35-36 region, only one of which is associated with N-myc amplification. Oncogene 1995;10:291-7.
17. Martinsson T, Sjoberg RM, Hallstensson K, Nordling M, Hedborg F, Kogner P. Delimitation of a critical tumour suppressor region at distal 1p in neuroblastoma tumours. Eur J Cancer 1997;33:1997-2001. (Pubitemid 28123442)
18. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, et al. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008;100:940-9. (Pubitemid 351957513)
19. Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of the chromodomain gene family, is preferentially expressed in the nervous system. Oncogene 2003;22:1002-11. (Pubitemid 36313144)
20. Woodage T, Basrai MA, Baxevanis AD, Hieter P, Collins FS. Characterization of the CHD family of proteins. Proc Natl Acad Sci U S A 1997;94:11472-7. (Pubitemid 27451023)
21. Garcia I, Mayol G, Rodriguez E, Sunol M, Gershon TR, Rios J, et al. Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Mol Cancer 2010;9:277.
22. Wang Q, Diskin S, Rappaport E, Attiyeh E, Mosse Y, Shue D, et al. Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res 2006;66:6050-62.
23. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466-77. (Pubitemid 23228250)
24. London WB, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, et al. The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. Cancer Lett 2005;228:257-66. (Pubitemid 41188449)
25. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol 2005;23:6474-80. (Pubitemid 46190238)
26. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4. (Pubitemid 14106392)
27. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111-6. (Pubitemid 16216827)
28. Hoerndli FJ, Toigo M, Schild A, Gotz J, Day PJ. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem 2004;335:30-41. (Pubitemid 39446227)
29. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 1991;9:581-91.
30. George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466-73. (Pubitemid 46190237)
31. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984;311:231-5. (Pubitemid 14087665)
32. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-63. (Pubitemid 29327593)
33. Shimada H,Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72. (Pubitemid 29327594)
34. Shimada H, Chatten J, NewtonWAJr., Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst 1984;73:405-13.
35. Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS, et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. J Clin Oncol 2000;18:1888-99. (Pubitemid 30261926)
36. Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 1999;18:4948-57. (Pubitemid 29425301)
37. Refke M, Pasternack SM, Fiebig B, Wenzel S, Ishorst N, Ludwig M, et al. Functional analysis of splice site mutations in the human hairless (HR) gene using a minigene assay. Br J Dermatol 2011;165:1127-32.
38. Caron H, van Sluis P, de Kraker J, Bokkerink J, Egeler M, Laureys G, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996;334:225-30. (Pubitemid 26030673)
39. Murphy DM, Buckley PG, Bryan K, Das S, Alcock L, Foley NH, et al. Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation. PloS one 2009;4:e8154.
40. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.
41. Buckley PG, Das S, Bryan K, Watters KM, Alcock L, Koster J, et al. Genome-wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large-scale epigenomic alterations localized to telomeric regions. Int J Cancer 2011;128:2296-305.
42. Gorringe KL, Choong DY, Williams LH, Ramakrishna M, Sridhar A, Qiu W, et al. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia 2008;10:1253-8.
43. Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 2008;3:210-5.
44. Wang J, Chen H, Fu S, Xu ZM, Sun KL, Fu WN. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma. Oral Oncol 2011;47:601-8.
45. Wang X, Lau KK, So LK, Lam YW. CHD5 is down-regulated through promoter hypermethylation in gastric cancer. J Biomed Sci 2009;16:95.
46. Zhao R, Yan Q, Lv J, Huang H, Zheng W, Zhang B, et al. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer. Lung Cancer 2011, doi:10.1016/j.lungcan.2011.11.019.
47. Bagchi A, Papazoglu C,Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007;128:459-75. (Pubitemid 46198889)
48. Mokarram P, Kumar K, Brim H, Naghibalhossaini F, Saberi-firoozi M, Nouraie M, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One 2009;4:e7012.
49. Wong RR, Chan LK, Tsang TP, Lee CW, Cheung TH, Yim SF, et al. CHD5 downregulation associated with poor prognosis in epithelial ovarian cancer. Gynecol Obstet Invest 2011;72:203-7.
50. Lang J, Tobias ES, Mackie R. Preliminary evidence for involvement of the tumour suppressor gene CHD5 in a family with cutaneous melanoma. Br J Dermatol 2011;164:1010-6.
51. Hogg RP, Honorio S, Martinez A, Agathanggelou A, Dallol A, Fullwood P, et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 2002;38:1585-92. (Pubitemid 34879144)
52. Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001;61:7277-81. (Pubitemid 32946526)
53. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-43. (Pubitemid 36792869)